Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 + HB1801 vs trastuzumab + pertuzumab as adjuvant therapy in resectable HER2-positive breast cancer
CTR20260576Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab, albumin-bound docetaxel in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
anbenitamabalbumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260576.